Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Actinobacillus succinogenes Uronate isomerase (uxaC) CSB-YP412874AUG
CSB-EP412874AUG
CSB-BP412874AUG
CSB-MP412874AUG
CSB-EP412874AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes 23S rRNA (uracil (747)-C (5))-methyltransferase RlmC CSB-YP412875AUG
CSB-EP412875AUG
CSB-BP412875AUG
CSB-MP412875AUG
CSB-EP412875AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes 33 kDa chaperonin (hslO) CSB-YP412876AUG
CSB-EP412876AUG
CSB-BP412876AUG
CSB-MP412876AUG
CSB-EP412876AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes Shikimate kinase (aroK) CSB-YP412877AUG
CSB-EP412877AUG
CSB-BP412877AUG
CSB-MP412877AUG
CSB-EP412877AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes ATP synthase gamma chain (atpG) CSB-YP412878AUG
CSB-EP412878AUG
CSB-BP412878AUG
CSB-MP412878AUG
CSB-EP412878AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes D-tyrosyl-tRNA (Tyr) deacylase CSB-YP412879AUG
CSB-EP412879AUG
CSB-BP412879AUG
CSB-MP412879AUG
CSB-EP412879AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes ATP-dependent protease ATPase subunit HslU (hslU) CSB-YP412880AUG
CSB-EP412880AUG
CSB-BP412880AUG
CSB-MP412880AUG
CSB-EP412880AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes Met repressor (metJ) CSB-YP412881AUG
CSB-EP412881AUG
CSB-BP412881AUG
CSB-MP412881AUG
CSB-EP412881AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes Orotate phosphoribosyltransferase (pyrE) CSB-YP412882AUG
CSB-EP412882AUG
CSB-BP412882AUG
CSB-MP412882AUG
CSB-EP412882AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes 30S ribosomal protein S3 (rpsC) CSB-YP412883AUG
CSB-EP412883AUG
CSB-BP412883AUG
CSB-MP412883AUG
CSB-EP412883AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes 50S ribosomal protein L5 (rplE) CSB-YP412884AUG
CSB-EP412884AUG
CSB-BP412884AUG
CSB-MP412884AUG
CSB-EP412884AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes 50S ribosomal protein L30 (rpmD) CSB-YP412885AUG
CSB-EP412885AUG
CSB-BP412885AUG
CSB-MP412885AUG
CSB-EP412885AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes 50S ribosomal protein L17 (rplQ) CSB-YP412886AUG
CSB-EP412886AUG
CSB-BP412886AUG
CSB-MP412886AUG
CSB-EP412886AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes tRNA (guanine-N (1)-)-methyltransferase CSB-YP412887AUG
CSB-EP412887AUG
CSB-BP412887AUG
CSB-MP412887AUG
CSB-EP412887AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes Membrane-bound lytic murein transglycosylase C (mltC) CSB-YP412888AUG
CSB-EP412888AUG
CSB-BP412888AUG
CSB-MP412888AUG
CSB-EP412888AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase (gpmA) CSB-YP412889AUG
CSB-EP412889AUG
CSB-BP412889AUG
CSB-MP412889AUG
CSB-EP412889AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes Na (+)-translocating NADH-quinone reductase subunit E, partial CSB-YP412890AUG1
CSB-EP412890AUG1
CSB-BP412890AUG1
CSB-MP412890AUG1
CSB-EP412890AUG1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes DNA-binding protein fis (fis) CSB-YP412891AUG
CSB-EP412891AUG
CSB-BP412891AUG
CSB-MP412891AUG
CSB-EP412891AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes Ribosomal RNA large subunit methyltransferase H (rlmH) CSB-YP412892AUG
CSB-EP412892AUG
CSB-BP412892AUG
CSB-MP412892AUG
CSB-EP412892AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Actinobacillus succinogenes Phosphoribosylformylglycinamidine cyclo-ligase (purM) CSB-YP412893AUG
CSB-EP412893AUG
CSB-BP412893AUG
CSB-MP412893AUG
CSB-EP412893AUG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>